SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Long-term Debt
Borrowings due after more than one year.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Long-term Debt · Q1 FY2026 · quarter ended Mar 2026
Long-term debt of $0 in Q1 FY2026
Q1 FY2026 long-term debt was $0.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
Long-term Debt vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 0.0% of total assets for SGP, versus a peer median of 9.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $5.07B USD | +2.9% | +28.9% | 36.6% | |
| Sep 2026 | $4.69B USD | +12.8% | -2.9% | 14.9% | |
| Jun 2026 | $102.84M USD | — | -49.7% | 11.2% | |
| Mar 2026 | $72.06M USD | +4.1% | +11.1% | 9.8% | |
| Mar 2026 | $36.74M USD | -7.2% | +6.6% | 33.5% | |
| Mar 2026 | $9.32M USD | — | -37.3% | 3.1% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $0 USD | — | — | 0.0% |
| Apr 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding SGP) | — | +3.5% | +1.8% | 9.8% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.